Opinion & analysis

J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says

What’s the meaning of “hypoallergenic”? Judges in the federal court Northern District have disagreed, with a judge recently siding with Johnson & Johnson’s definition of the term as part of an ongoing lawsuit. Find out more about the suit and its implications for your business in this article from Rose Sheet.

J&J Scores Early In ‘Hypoallergenic’ Case; Plaintiff’s Definition ‘Implausible,’ Court Says

Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens

Cosmetic Preservatives Crisis Creeping Into CIR Program

It’s Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

Paying For Gene Therapy: Will Pharma Be First In Line?

Bayer’s US Playbook: The Smart Way To Top-Line Growth

Pharma’s New R&D Models: Federating Innovation

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

New Reasons Not To Use EU MDR’s Four-Year Extension, But Comply Earlier Or Retire Products Instead